EPRX Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is13.02 USD with a low forecast of 11.02 USD and a high forecast of 16.03 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Eupraxia Pharmaceuticals Inc revenue for the last quarter amounts to -6.52M USD, increased 12.42

Eupraxia Pharmaceuticals Inc. EPS for the last quarter amounts to -4566933.00 USD, decreased -55.37

Eupraxia Pharmaceuticals Inc (EPRX) has 33 emplpoyees as of March 04 2026.

Today EPRX has the market capitalization of 457.76M USD.